CYP51A1 and parasitic infectious disease: Recent clinical trials investigating the efficacy of azoles (CYP51 inhibitors) to eliminate T. cruzi parasitemia resulted in an initial elimination of peripheral parasitemia that, unlike benznidazole the first-line therapeutic, was not maintained after cessation of therapy (Molina et al., 2014; Morillo et al., 2017; Torrico et al., 2018).